Earnings call transcript Q4 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day and thank you for standing by. Welcome to the Spectrum Pharmaceuticals 4Q 2022 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today’s conference is being recorded. to Grabow, conference Chief Executive like speaker to Financial now Michael today, Vice would hand over the your Officer. I President and ahead. go Please

Michael Grabow

Thank Chief and Sales Miller. Chief XXXX Officer, full Vice Tom on you, President, Vice Spectrum and Nora Executive call call. President Brennan; Executive and Senior today’s President With Erin me Officer, operator. year Spectrum’s are Riga; to Financial Welcome Marketing, earnings Pharmaceuticals and

year ended today, this financial the at Earlier through issued results release section press website release a call Relations the of accessed of XX, its detailing December and Spectrum press be the webcast This Investor sppirx.com. Spectrum XXXX. for a can

on materially these quarterly that forward-looking on reports and Form from involve like report inherent statements. make of this periods you placed we company’s implied statements in emphasizes identifies and materially performance differ This future any to not performance future notice Form-XXK reference will morning. notice results actual may Such cause forward-looking filings not We from and the reliance These statements statements or including past in in and are that major necessarily results factors company’s or should and to we of press future SEC Before would the undue cause on expressed results which actual those regarding them. which and annual and by may known uncertainties the projections release. without specific started, performance the get forward-looking unknown statements. limitation to risks or forward-looking be the such to included financial guarantees I forward-looking future statements encourage the review in the XX-Q events uncertainties, described differ today’s with risks

will one be completion of replay after at on available be for our year call. available The sppirx.com. webcast archived shortly will A website this telephone

this to topics webcast, company’s press listening on XX, to call refer may related the who please XXXX. releases March archived so the Spectrum For Since replay SEC the or of maybe discussed, those recent and announcements then, filings. is the most benefit to held made have

And Tom turn will over and Riga. I with to the CEO, President Spectrum’s that, call

Thomas Riga

morning everybody today’s joining Mike. for us Good on thank call. and you Thanks

As fourth review want and and year of full within I we begin our to I company. the are the quarter XXXX enthusiasm experiencing energy acknowledge

Our trajectory end the continued ROLVEDON. certainly is very fuelled earning XXXX. has ROLVEDON company of to has the provided the the quarter of The throughout launch and by the build launch a within positive first of momentum year to optimism

significant the organization. we a focussed key company still operational, has company amount been into commercial pivoted development A from growth Additionally, and business our core in investing a meeting experienced size objectives strategic focus fully our throughout as while XXXX of of to drivers. right point company the change a

In operating reporting the and we of XXXX and intentional today and was to resources XXXX, our expenses $XX launch are in capitalize The ROLVEDON. operating were reduction million. million our of on necessary XX% focus $XXX expenses

investing in continue launch maintaining management structure. we while the As of the and product operating disciplined to are very well and we into trajectory XXXX, lean positioned move lifecycle a

and combination strategic us to broader begin discipline allow ROLVEDON’s realize The will launch our maximizing financial of vision. to

single cancer treatments use and we commercialize patients of complacent, and for to not are develop portfolio We need. a product company aspire in

is further and the motivated of management day our to with success on future by optionality predicated ROLVEDON. are through fact study and largely understand the dosing our differentiate Both lifecycle and commercially the we brand. same However, that

we’ll a be the ready ROLVEDON’s eye opportunities. product’s is horizon our future Today, primary our as for use but success focus, on the we launch are springboard keeping to and

a with in over a market experience understanding biosimilar. the of long We team strategy acting is not ROLVEDON Regarding oncology a [Indiscernible] launched G-CSF enter to novel years product and is space ROLVEDON the with significant the the first this sub based in the that disciplined launch space. on XX exact

Vice from a moments color Sales charge. President the her of provide In Miller Senior for on is be will oncology the extensive XX launch. years more factor leading to and over our has few Marketing who you’ll on hearing growth Erin Spectrum Erin has been and have the experience, fortunate

for the The was fourth are ROLVEDON and early customers. quarter of with Net quarter were first from million. pleased the $XX.X we available, sales XXXX commercially the our quarter reception was

about As success for see customers To with early it's a is foundation we to systematic use. overall and a an to the measured product, increase of in both solid oncology an launch, users. largest breadth of the receptive indicator think set important along depth of being important by business, breadth the

That represent said, oncology total purchasing a of we including XX the ROLVEDON Those community XX% networks during alone approximately accounts launch quarter, three three the total clinic the saw market. targeted networks. top of

to that aware we just also ROLVEDON, it's While acutely the we reception customer early. with are that pleased are early

team the of front in of importance and success time. it the Our understands by is us, motivated over opportunities sustained

launch call and details results, to of let over more the key me Erin. For progress drivers our strategy, on turn the

Erin Miller

and I'm to be a nimble here team launch. maximizing experienced market who early results. very happy today ROLVEDON the Tom. producing to launching a We're progress with of you, and opportunities focused discuss Thank the are strategy with

continues more at As the we users That accounts end QX. the overall and the target of has number of Tom in doubled than to quarter, accelerate. XX breadth had mentioned, first

XXX commercial and to highly began those utilization ROLVEDON systems top connected depths, is connect networks. the through our who sales. key navigating allow would team. their grow appropriately using within Regarding continued quickly and pull and experience have are early systems in A our our in QX success sales factor that customers knowledgeable us representing we G-CSF knew to acting long XX% of There early

instability, with if already the we're appreciate the a and our price receptive recognizing highly that are customers our tremendous and value providers ROLVEDON of to In of messaging visibility. Many proposition services suite offering. proven market

short around for delivers creates which foundation As focus great value, predictable a and strategy centers our growth. continued result, adoption a and long-term both early a that provider

we with and results understanding strategy. Prior the of As each our behavior metrics, to acting we're evaluate hospitals. extensive customer critically in on non-XXXB aligned three community that we segments; of clinics, oncology early G-CSF launch, spent XXXB, focused the amount long finding an time launch sub are the

team oncology is change decisions Our of implement strategy make early engaged with product community on who executed segments our business poultry with can and and quickly. is all the [ph] clinics

increase Moving hospital on segment. is the to utilization space clinic within capitalizing while to the forward, opportunities our in also plan continue

specialty expand For instance, in the across utilization distribution and group purchasing first been able to networks we've quarter, organizations.

anticipate first segments. System of across and contracting all hospital IBM expanded our utilization Additionally, we're in process the with

This decisions. us product features a contracting, novel greater business to make and of a is long-term needed on allows pricing is not to to of flexibility gives As visibility independent and one that biosimilar us offer much short not the tied ROLVEDON which other products. customers unique reimbursement

As I and tailored earlier, mentioned over dynamics, stability customers time. to current predictability market given of are the pricing receptive value reimbursement contracting, and and

solidify long market market combined doing requires our ROLVEDON's factors current stock opportunity acting to grow utilization the and G-CSF the ROLVEDON, the features appropriate growth the with customers to multiple and dynamics, to position in Additionally, market. offer unique of team believe an so. they're We accustomed

would for challenges. without fact since One multiple we the positive, claims ROLVEDON with customers it’s knew long choose, there formidable is factoring encountered receptivity challenge market, be are and there growth after In currently miscellaneous J-Code. that to factor we've its not approval early competitors. is options While are submitted the a

market, ROLVEDON a offering permanent Customers own competitive assigned current reimbursement are J-Code. permanent remove the unique its documentation customers potential are to and the customers, because choose an recently a and to was welcomed also into X. simplified, J-Code barriers prefer which certainty. more utilization milestone it certainty a claim In and important with our April product, be customers. more J-Code, likely submissions will This by very goes new effect was for of

April permanent of in to very strong awareness speak when QX, exciting the our the and brand on NCCN to on just established include of ROLVEDON customer quarter. we important milestone in capability course urgency inclusion in in way understand supportive September, a been establishing launch look care in X. beginning the building executed treatment guidelines best the forward journey We've go a the It's of foundation. December, building added a will NCCN we're and accomplishments announced to team. for are brand In resource initial that standard our Cancer Network significant Approval success. by long the determining are and and a for an was guidelines. strategy, Comprehensive and our These and We a J-Code our The at guidelines and National followed confidence. inclusion another

financial XXXX to With to that, turn call the I'll over Nora now results. the discuss

Nora Brennan

ended year sales Thank the you Total were December XXXX million. net and the $XX.X for quarter XX, fourth for Erin.

royalties sales and was the During and December million sales with previously were research primarily any start-up packaging This expensed XX, ended freight of XXXX of with development. stability $X.X in with consisting ROLVEDON ROLVEDON, not which costs million, year and the and associated of net $X.X the quarter cost associated of include figure direct testing. did manufacture bio-burden the expenses of and associated costs,

million for the and $XX.X compared quarter $XX.X million expenses year million general million were as XXXX. $XX.X respectively, comparable in administrative to and and for $XX.X Selling, the and periods

decreases services other related January costs from The and resulting professional decrease in the general announced to lower reduction was primarily associated expenses personnel workforce with and expenses. due in XXXX, in

activities the accrued which were strategic expenses $XX.X drug $X.X in periods year, no payable us. million as XXXX, due quarter for XXXX and a provided in early-stage respectively $XX.X to longer comparable The personnel-related decrease by well for had the development million and lower reduction was program with substance million $XX expenditures research that Pharmaceutical workforce and poziotinib, the for Total as XXXX. January by Limited Hanmi and million is compounds, as and and the began compared associated been concession to during ROLVEDON. for in during restructuring

of $XX.X $X.XX XX, for million for the loss loss share continuing from or per $X.XX per the December from share comparable million XXXX ended operations operations to or Net period compared net continuing a XXXX. quarter $XX.X in was

or was for net million loss from compared from $X.XX million loss the Net share $XX.X per the or operations period XXXX. operations share, continuing continuing to in $XXX.X per comparable $X.XX of for year

to and cash which the approximately due decreases working million decrease of offset on-going and strategic $XXX.X compared burn XXXX. to Operating reduce our in activities efforts changes million $XX overall was by as cash net XXXX was in to use non-cash was in decrease burn company loss, and in the net in driven charges. the primarily by cash operating The capital

$XX.X securities. the with cash, in ended equivalents quarter approximately cash million fourth and We marketable

With XXXX. we tranches remaining at company are Capital two financing ROLVEDON. access available cash $XX financing we achieved XXXX. points that have fund The drawdown operations until have November certain various additional revenue XX, our believe the Partners, assuming SLR we of million to for to resources this discretion We with milestones for at and hand, on an reserves through

please open the questions. With that for operator, line

Operator

One Instructions] will for question [Operator And from our first Maury our Jefferies. first question. moment Raycroft Certainly. of come

Your line open. is

Maury Raycroft

the Hi, good on thanks morning. my progress. for Congrats taking questions. And

are what what enable of you predictability think all expectations second the And Just quarter, and seeing wanted provide to place earnings call? having in post J-Code to guidance quarter second April by you're on that through X you ask pre do on J-Code your reimbursement? would

Thomas Riga

so Maury question. thanks much for Hey, the

a measure just is time at that what the because the think I their means removes J-Code and clarity the the X, April at to things the documents accomplishment ultimately product. cycle achieving like required level additional the time think was avoids The customer a big of I for payments. brand important that's barrier to in think using in delays the And claim think payment. Getting that customers here. I I

our our It for And the receptivity. think just X, early we're in permanent think with all out from doesn't our But J-Code, we to energy a the we kind few with guidance; I that's we enthusiasm utilization get as on measures prior that fueling are under or giving and of seeing quarter, fuels remove to utilization. seeing hurdle customer the ones shared comfort belt of the giving that you and miscellaneous we fourth the it whether engaging of J-Code a team's into to quarters anticipate they're with one, customers. our to give breadth So and despite going our J-Code sales it going be continued the the NCCN guidance. want us barrier perspective, April recorded excitement receptivity the effect today I customer a our depth the

Maury Raycroft

and you contract that and elaborate it. sense. what contracts getting on mentioned into the Can a Got lot Makes those durations And of with visibility longer accounts pricing contracting. are tailor term look you decisions like?

Thomas Riga

that an Yes, value the fact of is that think once are entire into the think is put that what independent I control established, the And discounts in is, own so that's think BLA I we non-biosimilar. are we that's, here the direct I ASP market. proposition central we our means our

So not reliant over discretion, average selling on time price any is impact we're else's sole to our decision. at anybody

handle that we us. early been if is have needed here time we ASP anything will how long the that's has think something and fact And we payers, users, over view you with by those example, third the For the provide end feedback stability track how decisions made but to that's marketplace, been because stable. customer a be this I they centrally think discount appreciate I party

Maury Raycroft

the in payers with you been wondering sense it. queue, think about and question to customers? versus how how bio-similar and me just as with conversations you pricing but back hop Makes going me. negotiate Last have Got initial for I'll

Thomas Riga

that I they're certainly stakeholder. important think think an I Yes,

provider importance recognizing is is, I'll the Erin strategy, centered strategy Our give color third around payers around have of progress we've centric engaged let party made. we a some but the them.

Erin Miller

Thanks payers an mentioned, this are Tom great question. market. And in as stakeholder Tom. It's a important

learned business target We will not which lives. with, there payers strategic insured XXX% do XX% will our we've represent total we aligned. is that because of payers, of have that engaged interests our be not engagement are What with from

understand said, important being stakeholder. That do we an they're

that payer we're the providing agreements focus while Those have on within providers, three market. ensuring stability access this our strategy, agreements our of also We to and place. keeping align and with goal predictability additional in

Maury Raycroft

helpful. It's very Thank it. all you Got much.

Thomas Riga

Thanks Maury.

Operator

for next come And our question. Edward moment One from next our question will White.

open. is line Your

Edward White

for Good morning. Thanks taking my questions.

how working as are through the following the any way you be force finding sized? do Or make to right SG&A additions? So your thinking results? that quarter that first the you're launch, have we see is expenses, fourth just should you And Tom is question, your directionally about sales perhaps you

Thomas Riga

the Hey, Ed for thanks thanks question. for

Let one me me at a handle let those time.

the achieve In what pretty to largely really of terms on of be success. was of driven our size, going the had gate. a understanding we One market top line the sales. necessary It out of things. seeing think sales And and the two was strategy outside speak we to to right strategy believed is that we're disciplined by number, I

the we as think tentacles, point, into is But executing other quite expand expand continue I we well. So business, team your the And to are we'll of and to we parts lean. our evaluate it.

the think I of particular your we're of SG&A the I that on pretty draw would about think as XXXX, to exists you line. comfortable with today. the force aspect that don't growth attention sales I that And significant size anticipate

that poziotinib That's $X.X what As with in here came seeing you look included QX. R&D de-prioritization number. at you're is expenses, at in think the line million in largely I associated is of largely the that

offsetting increases I R&D with the So at of to SG&A. to see in reduce would expense expect continue line level XXXX

two. I something let there's else, think if those And me are know. your

Edward White

done. of just cancer what are R&D, that expectations? portfolio goals and maybe speaking on internal your And give us you of you current in mentioned are opportunities. just development those You then your can treatments; R&D business thoughts had at or looking efforts Those, R&D potential were our

Thomas Riga

focus around their through pediatric XXXX have around day expectation so the same company, two PMR lenient we really R&D we've in a ROLVEDON. is scalable the as of dosing group. My driven It's into Yes, study move maintained change the for that the and centered we things.

aspire had the group execute. is We to central will activities mentioned kept today. be starting we're success, will with prepared over be optimistic what this product remarks just scalable, in to, ROLVEDON. and single we because is how happen I it's think discussions intentionally obviously those do But So company those And stopping ROLVEDON not decisions and focus time. to our I which a all we and with primary

Edward White

Great, question. Tom, my thanks for taking

Thomas Riga

Ed. Thanks,

Operator

of Benjamin from One moment our question for Securities. And Reni comes next our next question. Bennett JMP

is line open. Your

Reni Bennett Benjamin

first team your mentioned launch. on in, number and you that of jumping congratulations I quarter doubled. questions. thanks the prepared in and in the Maybe just, straight And the guess accounts Tom taking two remarks related I that questions Hey, think has for

think that is doubling would accounts, revenues for of are different is doubling about this XXX we translating quarter? first we not, be considering? of the accounts, -- about make what that should potential to the So it? Or, a Can the what the are if factors

of how are as progress are, as doubling targeting? total accounts the this that number that we, what's total accounts, number? And we And think we much have made towards you about of

Thomas Riga

questions Yes, Ren. the thanks for

doubling not as of an a I because, I sales to is would think an one; the account. you Ren equate of not a first accounts doubling know, account

them of networks just XX% within top community sale. example, in of Some the three the represent the oncology

think the of the metric, I look really be matter. have we we and So at and long-term intra internally, segment across both one breadth to value you it's utilization, segments that because reason customer to share that to particular and the increase wanted intra for for successful, goals,

we're those we that direction So to we go metrics seeing in that the go. want

question, breath So numbers. on based those growth? increases. I But we making you kinds your Absolutely, with of to assessments don't should those do be revenue think expect

Reni Bennett Benjamin

viewing various unfree are the as constituents, XXXB, Okay. the end community I year, might of about of be and those into segments? guess, an by each just right, it's what thinking And we're the XXXB the you the in kind penetration of how

Thomas Riga

systematic. I think planning be to we're, we're

as strategy community And our really playing speed the I think, research launch. making of with we've it's out to we've been, up proposition. consistent to decision start as and leading expected, given our the largely was oncology to been the with very value receptivity that

in mentioned had her prepared Erin as encouraged I'm think I remarks.

coming online the hospital in Our first IBN quarter. here first is

all three engaging segments. those are we So of

decisions the there's within product or or of challenge launching is segments, there's not to either engage. decisions of the these of each reality think engage timing a I

So see the do while making tried decision a core process what some within to other the our up is fruition. really of and come see one, segment to And of we've work gain to interest initial ourselves if to the there's hospitals strategy we to process, each set in that PNT to you're community. opportunity an the enable of through segments, starting

of year, to that's to through But end be the segments expect of three all the business. that's of place the it And to that's I think followed the As going going driver trail the the to hospitals. on I think us then by indicators in are would infused the lead success relates would early I -- to community the be end greatest be XXXB. going be non-XXXB

Reni Bennett Benjamin

is Got place it. takes the anything, then but obviously, the guess just maybe in in with don't be from quarters. in I impacted took see that final might way have not there might in us. segment, a that subsequent there place I wrong. positive we And anything that one revenues one But might that particular this stockpiling think Is G-CSF I'm quarter fourth

to Just fourth launch? trajectory seasonality of one of up trying have quarter if or we about time of as was if sort that the opposed there that get quarter from any occurred in the first any sort should to anything be as that thinking the things that

Thomas Riga

to point No, I to think number. that I there's out Ren dynamics in that you

at wholesale product. there's interest initial wholesalers level, initial stockpiling there's it's when or stockpile, there's in not to interest So the stockpile To the some of customer's point becomes your always available. the that a product purchases not happen

governor's met things the So customer the and there's pure level at which we patterns oncology by and abnormal through pure there's wholesale in product any -- mechanisms see level buy bill don't the that. the that But tight happen. for just purchasing by patterns any purchasing

the out second quarter. the month let So ASP the week third me of comes of explain.

paid get function I that of dealing And the of the contracted when a think money. mechanism that quarter of you're oncology; see cost previous the in that's than inevitably larger I you timing. made two. and month time the third be how of a that with decisions rebates lot think are will And of

you rebate over shrink the this products, be a will that think will with across I the growth whether factor, expect month of contracted I typically And time. or would than month that especially I first So think the third the be two. biggest see reality higher ROLVEDON, business, are quarter any being third a the But factor to think component. those it growth be will that of

Reni Bennett Benjamin

Got for it. Thanks the questions. taking

Operator

come Prakhar for from And next Agarwal Fitzgerald. One at our of next moment question. our Cantor question will

is Your open. line

Prakhar Agarwal

team quarter. my morning on taking the thanks good congrats And Hi, question. for and

So three first access question, following bear up the question, I think on place. the in agreements

lives covered up. the of you And follow a year? now? right to do the percentage where what I represent expect quick these had end by be do of So And

Thomas Riga

so if me Erin let try let Yes, something add. there's want and, to me you

cost in increase to desire think the to high, is So their a the I within look the is payer coverage think has about a the make a a where eligible payer, the of and to receptivity book that is geographies us predominant the agreements. is there the that there from way is a population driver we and end user for those payer want

the third So much centric to enables provider it's that a based customer the on to receptivity engage payer very product. party us strategy

those mentioned, payer had in Erin followed for agreements it So signed actually pattern. exact agreements, we that that that

their have engage with using had our one to with, of So contract who with the may deeper it those customers payers. a payers. those who to negotiations concentration aspire of That's started the in hurdle but signal their use it product business, with and have engaged a predominant product

relates that's end be largely strategy. total the going So of think end on we'll I covered with the as where up dependent year, it to at lives to

as that So within customers, as eligible within as our the and that critically stakeholders, payer Erin, restrictions look well the are make to evaluating then in the payer. this case, else? agreements population customer anything our deepen be business, that beneficial offs the we continue to will position for have we

Erin Miller

predictability market. stability say have we this just and within that I No, focus that is the

that to with focus, payers engage. and that engage, to discussion willing that understand are we are have willing So absolutely

Prakhar Agarwal

with non-XXXB? discussions? the there your between that issue and from questions. Is a barriers any non-XXXB other timing PNT what question, versus Appreciate receptivity the hospital been on the has second And work decision initial or you. it XXXB uptake been Thank you any segment to on And based XXXB through? need has the committees Understood. mostly in difference

Thomas Riga

great question. Yes,

think is timing. one I

that So real. is PNT is real. very

challenges faces. I strategic think one that there's other practical

going of least a cost principal alternative. We be cost is driver are are to decisions never alternative. And that then least the systems there hospital

think are I going to those challenge. a be

I think of more a and there are also segment XXXB are centric value their that non hospitals, in approach. both

over Given many community that think the of of consolidation years become hospitals have the have the of been large that the IDN I clinics thinking has infiltrated many systems.

So I I have today we're we're think But going the think of certainly strategic in hospital uptake the about in segment, to to face is delusions initial engage. that in we that how we grandeur segment. don't the be And timing. going of challenge

Prakhar Agarwal

you Thank

Operator

One of moment. from [Indiscernible]. come Kazmi question Suhel And will next our

Your line is open.

Unidentified Analyst

of morning. a good is This my Hi, end. questions from couple [Indiscernible] asking

day So if and dosing enrollment any congrats the data addressed. hear the been us might I from study, same expansion quarter But so both we provide earlier the on you open the the be could when bunch an curious team, study have I know and on great. is label, think some would just phase. you of questions from a either on initial color update have this from our

Thomas Riga

for study running. about this in We're one. is thanks Yes, optimistic question. the up That

efficacy the and this of interim that's pre-specified We have back of year. a projected half on safety review that's

so think particular mechanism. the and fit realities that I utilization delivery arm, mentioned, you the both minute into we XX data only As the of did do practical expansion the

early the some the in Miami what on performing that is we perform, to largely was so inform presented with label could product we're we chemotherapy post the think minutes presented drug the and open We're the is that's of data year. study arm into XX what that to if in believe visibility of year, going healthy half and that So half the then second initially, have expanding. the line expecting I in second

Unidentified Analyst

be the Maybe as the you brief a distribution Thank the it XXXB, the data we here, positive about different follow community across impact see oncology Very channels setting talk helpful. non-XXXB up, you. assuming hospitals. some can or

Thomas Riga

I I contingent to have what think been the going think your a we on on would outcome, regulatory in be whether chat whether question path, upon FDA first publication, has it's the specific with dosing, thing conviction see if the path it's forward, more really we that that about data. a depending

focused bag, as our I with given to XX think the today. really label, chemo. it and distribution, we post with seeing are have we're relates hours that in is what non-inferiority pleased and commercialization So we what

So of I that be, what think here make it we the the we that's in seen performance and that work. strategy. should is the the data should year, the would earlier produced near alone, strategy be obviously in step we and visibility have in executing strategy back in that the approach, aggressive overwhelmingly term, positive, that representative the be to next obviously our we've on we hoping then a of there we of half are underwhelming, could be would once take action and data too. the decision But what we're appropriate

Unidentified Analyst

all congratulations and on much, so the thanks Excellent, progress.

Thomas Riga

question. the Yes, thanks so much for

Operator

to for closing would I'm remarks. Riga, like CEO showing And further conference no the turn to back not Tom questions. I

Thomas Riga

Hey your on as participation call everybody today your in interest the for well as thank you Spectrum.

EDSM and On the and a strong at quarter, [Ph] we're looking is with to of future. heels high the the launch forward our and company customers,

you always, reach to questions, Thanks out. for feel As have joining. free if

Operator

you call. for Thank this today's concludes participating. conference And

may now disconnect. You

Spectrum Pharmaceuticals (SPPI) 22 Mar 232022 Q4 Earnings call transcript